Rxo (RXO) Cash & Equivalents (2021 - 2026)

Rxo (RXO) has 6 years of Cash & Equivalents data on file, last reported at $21.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 31.25% year-over-year to $21.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 million (up 31.25% YoY) and the FY2025 annual result came in at $17.0 million, down 51.43% from the prior year.
• Cash & Equivalents improved to $21.0 million in Q1 2026, from $17.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $187.0 million in Q3 2022 to a low of $5.0 million in Q4 2023.
• A 5-year average of $56.0 million and a median of $25.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 94.9% — and 2024, when it surged 600.0%.
• Tracing RXO's Cash & Equivalents over 5 years: stood at $98.0 million in 2022, then slumped by 94.9% to $5.0 million in 2023, then surged by 600.0% to $35.0 million in 2024, then slumped by 51.43% to $17.0 million in 2025, then grew by 23.53% to $21.0 million in 2026.
• The last three Cash & Equivalents figures came in at $21.0 million (Q1 2026), $17.0 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.